INFO & CONTACTS:  +39 02 2390 1

Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations

Phase: Phase III clinical trials

Principal Investigator: Dott.ssa Mazzeo Laura

Main Facility: Oncologia Medica Toraco-Polmonare

Drug: Zongertinib

Pathologies: Lung cancer

Phase III randomized clinical trial 1:1 of the use of Zongertinib (selective HER2 tyrosine kinase inhibitor) compared to standard reference treatment (IMMUNOTHERAPY) in patients with Non-Small Cell Lung Cancer (NSCLC).

Last update: 13/07/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe